Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 6/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | PTAFR | P25105 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4391588 | 0.92 | KMT2A (0.55) | KMT2ANAMPTSMN1; SMN2ALDH1A1MMP13 | |
| SCHEMBL5822605 | 0.89 | MAPT (0.46) | NAMPTHDAC2HDAC8HDAC6JAK1 | |
| SCHEMBL3961441 | 0.84 | RAB9A (0.41) | KMT2ANAMPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL14357068 | 0.83 | KMT2A (0.44) | KMT2ANAMPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4398524 | 0.81 | NAMPT (0.41) | KMT2ANAMPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL5822526 | 0.80 | TP53 (0.49) | KMT2ANAMPTRAB9ASMN1; SMN2NPC1 | |
| SCHEMBL4391900 | 0.80 | SIRT1 (0.59) | KMT2ARAB9ANPC1ALDH1A1MEN1 | |
| SCHEMBL4401795 | 0.80 | RAB9A (0.40) | RAB9ASMN1; SMN2NPC1ALDH1A1MAPT | |
| SCHEMBL4391355 | 0.79 | TP53 (0.47) | KMT2ARAB9ASMN1; SMN2NPC1ALDH1A1 | |
| SCHEMBL4391824 | 0.78 | RAB9A (0.45) | KMT2ARAB9ASMN1; SMN2NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | LEXICON PHARMACEUTICALS, INC. | 2009-12-10 | — | — | US | disclosed |
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | LEXICON PHARMACEUTICALS, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20070049608-A1 | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. | 2007-03-01 | — | — | US | disclosed |
| WO-2006124897-A2 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITION | LEXICON GENETICS INCORPORATED (US) | 2006-11-23 | — | — | WO | disclosed |
| US-20060258691-A1 | Methods and compositions for improving cognition | LEXICON PHARMACEUTICALS, INC. | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153811-A1 | methods for treating, managing and preventing cognitive impairment associated with various diseases and disorders, age-associated memory impairment, and dementia. | CHAT, PSEN2, PSEN1 | KMT2A 651/4885NAMPT 1238/4885RAB9A 1214/4885 |
| US-20090306100-A1 | METHODS OF TREATING SCHIZOPHRENIA | CHAT, GAP43, GRIN2A | KMT2A 464/4885NAMPT 1355/4885RAB9A 1054/4885 |
| US-20060258691-A1 | Methods and compositions for improving cognition | PSEN1, PSEN2, APP | KMT2A 426/4885NAMPT 2406/4885RAB9A 808/4885 |
| US-20070049608-A1 | Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use | DPYD, TYMP, PNKP | KMT2A 4307/4885NAMPT 353/4885RAB9A 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.